Artivion (NYSE:AORT) Shares Gap Down After Analyst Downgrade

Key Points

• Artivion shares fell sharply after Citizens JMP cut its price target from $48 to $42, though it maintained a Market Outperform rating. Shares opened at $22.19, down from the prior close of $25.33, and later traded near $21.78.
• Analyst views remain mixed: the stock carries a MarketBeat consensus rating of Moderate Buy and an average price target of $40.57, while some firms have issued downgrades or sell ratings.
• Artivion’s third-quarter revenue rose 9% year over year to $123.8 million, beating estimates, but profitability was weaker: adjusted EPS of $0.08 missed the cited consensus, and the company reported a $7.9 million GAAP net loss.

Artivion, Inc. (NYSE:AORT - Get Free Report) shares gapped down prior to trading on Friday after Citizens Jmp lowered their price target on the stock from $48.00 to $42.00. The stock had previously closed at $25.33, but opened at $22.19. Citizens Jmp currently has a market outperform rating on the stock. Artivion shares last traded at $21.7750, with a volume of 167,974 shares changing hands.

A number of other research analysts also recently issued reports on the company. Jefferies Financial Group started coverage on Artivion in a report on Tuesday, October 20th. They set a "buy" rating and a $31.00 price objective for the company. Weiss Ratings cut Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Needham & Company LLC reaffirmed a "buy" rating and set a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Finally, Citigroup reissued a "market outperform" rating on shares of Artivion in a research report on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Artivion presently has an average rating of "Moderate Buy" and a consensus target price of $40.57.

Insider Buying and Selling

In other Artivion news, CEO James P. Mackin sold 70,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer directly owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Andrew M. Green sold 11,480 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the transaction, the senior vice president directly owned 40,160 shares in the company, valued at $1,002,795.20. This trade represents a 22.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 90,460 shares of company stock worth $2,557,366. Corporate insiders own 6.30% of the company's stock.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analyst estimates of about $121 million. Artivion also projected 2026 revenue of $484 million to $492 million, signaling continued growth. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company is preparing to launch its NEXUS aortic product in January 2027, a potential growth catalyst as it expands its product portfolio. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Profitability was weaker: Artivion reported a GAAP net loss of $7.9 million, while adjusted EPS of $0.08 fell short of Zacks’ $0.11 consensus and compared with $0.16 a year earlier. Adjusted EBITDA declined 8% to $22.5 million, which may temper the positive revenue news. Artivion lags Q3 earnings estimates
• Negative Sentiment: Canaccord lowered its price target on AORT to $30, a sign of reduced analyst expectations that could add pressure despite the company’s revenue growth. Canaccord lowers Artivion price target

Hedge Funds Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Maryland State Retirement & Pension System bought a new position in shares of Artivion in the 3rd quarter valued at about $245,000. Penn Capital Management Company LLC raised its holdings in shares of Artivion by 58.0% in the 3rd quarter. Penn Capital Management Company LLC now owns 34,431 shares of the company's stock valued at $786,000 after purchasing an additional 12,638 shares during the period. Fulcrum Asset Management LLP bought a new stake in shares of Artivion in the 3rd quarter valued at about $49,000. Oregon Public Employees Retirement Fund lifted its stake in Artivion by 12.3% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 10,929 shares of the company's stock valued at $249,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Vise Technologies Inc. acquired a new stake in Artivion in the 3rd quarter valued at about $225,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Price Performance

The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.03 billion, a P/E ratio of -301.21 and a beta of 1.31. The business has a fifty day moving average of $23.67 and a 200 day moving average of $29.09.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.14. The business had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company's products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.